{"title":"Overview of Critical Parameters for the Design and Execution of a High-Throughput Screen for Allosteric Ligands","authors":"Andrew Alt","doi":"10.1002/cpph.12","DOIUrl":null,"url":null,"abstract":"<p>Allosteric ligands modulate the activity of receptor targets by binding to sites that are distinct from the orthosteric (native agonist) binding site. Allosteric modulators have potential therapeutic advantages over orthosteric agonists and antagonists, including improved selectivity, and maintenance of the spatial and temporal fidelity of native signaling patterns. The identification of allosteric ligands presents unique challenges because of the requirement for screening in the presence of an orthosteric agonist, the small signal window that is produced by many allosteric modulators, the proclivity of allosteric modulators to exhibit activity switching within a chemotype (e.g., one compound may be a positive allosteric modulator while a close analog is a negative allosteric modulator), and probe dependence (differential interactions with different orthosteric agonists). Described in this unit are emerging strategies for the identification of allosteric ligands by high-throughput screening (HTS), including the use of multiple-add/multiple-read HTS assays and tool molecule-based screening formats. © 2016 by John Wiley & Sons, Inc.</p>","PeriodicalId":10871,"journal":{"name":"Current Protocols in Pharmacology","volume":"74 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2016-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cpph.12","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpph.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 6
Abstract
Allosteric ligands modulate the activity of receptor targets by binding to sites that are distinct from the orthosteric (native agonist) binding site. Allosteric modulators have potential therapeutic advantages over orthosteric agonists and antagonists, including improved selectivity, and maintenance of the spatial and temporal fidelity of native signaling patterns. The identification of allosteric ligands presents unique challenges because of the requirement for screening in the presence of an orthosteric agonist, the small signal window that is produced by many allosteric modulators, the proclivity of allosteric modulators to exhibit activity switching within a chemotype (e.g., one compound may be a positive allosteric modulator while a close analog is a negative allosteric modulator), and probe dependence (differential interactions with different orthosteric agonists). Described in this unit are emerging strategies for the identification of allosteric ligands by high-throughput screening (HTS), including the use of multiple-add/multiple-read HTS assays and tool molecule-based screening formats. © 2016 by John Wiley & Sons, Inc.
设计和执行高通量变构配体筛选的关键参数概述
变构配体通过结合不同于正构(天然激动剂)结合位点的位点来调节受体靶点的活性。变构调节剂比正构激动剂和拮抗剂具有潜在的治疗优势,包括提高选择性和维持天然信号模式的时空保真度。变构配体的鉴定面临着独特的挑战,因为需要在正构激动剂存在的情况下进行筛选,许多变构调节剂产生的小信号窗口,变构调节剂在化学型中表现出活性切换的倾向(例如,一种化合物可能是正变构调节剂,而接近的类似物可能是负变构调节剂)。探针依赖性(与不同正位激动剂的不同相互作用)。本单元介绍了通过高通量筛选(HTS)鉴定变构配体的新兴策略,包括使用多次添加/多次读取HTS检测和工具分子筛选格式。©2016 by John Wiley &儿子,Inc。
本文章由计算机程序翻译,如有差异,请以英文原文为准。